Grading CRS After CAR-T Cell Infusion
Amara is 13 years old (45 kg) with relapsed B-ALL, day 4 after tisagenlecleucel infusion. She has had fever 39.8-40.5 C for 18 hours, heart rate 138, and BP 88/48 that rose to 100/60 after one 10 mL/kg normal saline bolus. Her SpO2 is 93% on room air and she now requires 2 L/min nasal cannula. She has gained 1.5 kg since admission. Labs: ferritin 9,200 ng/mL, CRP 187 mg/L, creatinine 0.8 mg/dL (baseline 0.5). She is alert and oriented and answers questions appropriately. Blood cultures are pending; she has had two doses of empiric cefepime. The fellow asks whether she meets criteria for tocilizumab.
1. Assign a CRS grade with justification, and state whether tocilizumab is indicated.
Read the worked answer
Grade 2 cytokine release syndrome. Under the ASTCT consensus grading:
- Hypotension: present but responding to fluids and not requiring a vasopressor -- that puts her no higher than grade 2 on the hemodynamic axis.
- Hypoxia: requiring low-flow nasal cannula -- also grade 2 on the respiratory axis.
- Fever alone does not drive grading once CRS is present, but it confirms the syndrome.
- Grade 3 would require a vasopressor (single agent) or high-flow/non-rebreather/venturi oxygen. Grade 4 would require multiple vasopressors or positive-pressure ventilation.
Yes -- give tocilizumab. Grade 2 CRS is a treatment threshold in CAR-T recipients, and the drug is dosed by weight: 8 mg/kg (maximum 800 mg) for patients 30 kg or above, so 45 kg gives 360 mg. Do not wait for cultures to finalize; delaying anti-cytokine therapy while cultures pend allows capillary leak and progression. Continue broad-spectrum antibiotics and the sepsis workup in parallel -- CRS and sepsis are clinically indistinguishable at the bedside, and both are treated simultaneously.
Caution areas: tocilizumab is not for neurotoxicity, and blood counts/LFTs should be tracked because the IL-6 surge and its blockade affect liver enzymes and coagulation. Also prepare for a second dose if hypotension recurs after the first.
2. What findings in the next 12 hours would change your management, and what would you add?
Read the worked answer
Escalation triggers on two axes:
Hemodynamic: hypotension that no longer responds to fluid boluses and requires a vasopressor moves her to grade 3. In practice this means she should already be in a monitored setting with an arterial line or frequent noninvasive pressure monitoring, an accurate hourly urine output, and careful total fluid accounting -- she has already gained 1.5 kg, so continued large-volume boluses risk pulmonary edema, and the team should think about the balance between resuscitation and capillary leak.
Respiratory: oxygen requirement rising to high-flow nasal cannula, non-rebreather, or any positive-pressure support moves her to grade 3-4 and warrants ICU transfer.
Management additions at that point: repeat tocilizumab if the hypotension recurs (up to three doses in 24 hours is a common ceiling, per protocol), and add corticosteroids (for example dexamethasone 10 mg/m2 or methylprednisolone 1-2 mg/kg/day) for grade 3 CRS that does not improve promptly, or for any grade with life-threatening features. Refractory hypotension should prompt discussion of anakinra or other salvage agents with the CAR-T team.
Escalation criteria I would state explicitly to the fellow: any need for vasopressors, any oxygen escalation beyond low-flow, rising creatinine with falling urine output, new confusion, or a rapidly rising ferritin/CRP trajectory. Also ensure the bedside nurse knows not to give additional fluid boluses without a plan, because that is the reflex that turns grade 2 into a pulmonary edema problem.
3. Overnight she becomes confused, cannot name the month, and has one episode of garbled speech. How does this change your assessment and plan?
Read the worked answer
This is ICANS (immune effector cell-associated neurotoxicity syndrome), a separate syndrome from CRS that often follows or overlaps it. The clinical picture -- acute onset of confusion, disorientation, and expressive language difficulty -- is the classic pattern in a CAR-T recipient in the first days to weeks after infusion.
First, do not assume it is ICANS alone. Rule out the emergencies that mimic it: hypoglycemia, electrolyte disturbance (sodium especially), hypoxemia/hypercarbia, sepsis with delirium, and intracranial bleed or infection in a patient who is likely thrombocytopenic and immunocompromised. Check glucose and electrolytes now, review platelets and coagulation, and get urgent imaging.
Then grade and document it. Use an ICE (immune effector cell encephalopathy) score, which for her age means orientation, naming, following commands, writing, and attention. This must be tracked at fixed intervals, not casually -- trend is what drives treatment. Ensure seizure precautions and a low threshold for EEG, since subclinical seizures are common.
Treatment differs from CRS: tocilizumab does not treat ICANS and may worsen it. First-line therapy is a corticosteroid (dexamethasone or methylprednisolone per protocol). Escalate to ICU-level monitoring, and discuss additional agents with the CAR-T team.
Sequence to communicate: the presence of concurrent CRS should still be treated with tocilizumab, but the neurologic deterioration is a steroid indication. Moving her to a unit with continuous monitoring and neurologic checks every 1-2 hours is part of the treatment, not a formality.